Clinical, Legal and Ethical Implications of the Intra-Ocular (Off-Label) Use of Bevacizumab (Avastin)–a South African Perspective (Original Articles) (Report)

Clinical, Legal and Ethical Implications of the Intra-Ocular (Off-Label) Use of Bevacizumab (Avastin)--a South African Perspective (Original Articles) (Report)

Choroidal neovascularisation is a potentially visually devastating element of various forms of eye pathology. Recent research has focused on neurovascular age-related macular degeneration (AMD) as a cause. AMD can be classified as being exudative (wet) or atrophic (dry). Wet AMD is characterised by a pathological process in which new blood vessels develop in the choroids, causing leakage of fluid and haemorrhage under the retina and leading to localised serous detachment and loss of central vision. Vascular endothelial growth factor (VEGF) stimulates growth of neovascular membranes. Treatments have until recently yielded disappointing results. Ophthalmologists are using intra-ocular injections of bevacizumab (Avastin), an anti-VEGF, to treat AMD. Avastin appears to be safe and effective in the short term, but its intraocular administration is entirely off-label. Avastin is registered for treating metastatic colorectal and breast cancer.

Clinical, Legal and Ethical Implications of the Intra-Ocular (Off-Label) Use of Bevacizumab (Avastin)--a South African Perspective (Original Articles) (Report)



Here is Download Link

Leave a Reply

Your email address will not be published. Required fields are marked *